Finding the Answers

Adopting a structured and streamlined approach to medical writing can help increase efficiency when responding to authority questions in the marketing approval process.

A great amount of effort goes into preparing a submission dossier to apply for marketing approval of a medicinal compound. However, process doesn’t stop once the dossier goes out the door. In fact, sometimes, that is when the really tricky part begins. After receipt and review of the dossier, the authorities respond to the sponsor with their questions, which usually address the weaknesses or sticking points of a development programme. At this point the team faces the biggest challenge of all: writing and coordinating a set of responses to these questions that make the science clear and demonstrate to the reviewers that the risk benefit-assessment is well-founded.

Review Timelines

To adequately plan for and streamline activities associated with preparing responses, the regional variability in how questions are posed to the applicant need to be considered. For a European centralised procedure, the review process follows a strictly defined timeline (1). Review begins on day one (clock start), and the initial assessment report from the rapporteur is sent to the Committee for Medicinal Products for Human Use (CHMP) and to the sponsor on day 80. The assessment report includes a preliminary list of questions and provides the first insight to the reviewers concerns.

Figure 1: Techniques that streamline the process of responding to authority questions

- Submit the dossier
  - Work on the dossier
  - Make a list of potential questions

- Receive preliminary questions from the rapporteur
  - Plan the response team
  - Focus on the potential questions – develop a strategy to answer them

- Receive final list of questions from CHMP
  - Prioritise the preliminary questions – determine which are most challenging and most likely to stay
  - Gather information to answer the questions

- Pre-submission
- Planning
- Getting started
- Final relay race

Day 1
Day 80
Day 120
regarding the dossier. A consolidated and final list of questions is sent to the sponsor on day 120 from the CHMP (clock stop). Applicants then have three months to respond to the questions (2). An additional period of up to three months can be requested if there is appropriate scientific justification, but extensions beyond six months are not normally accepted. With such a tightly defined process, the timing of questions is predictable and, because a set of preliminary questions is shared with the applicant on day 80, the applicant has an advance warning period of 40 days to address key questions before the start of the three-month response period. This makes it easy to plan resources and offers more time to develop a strategy for answering the questions.

The timeline for review is more loosely defined after submission of a drug application dossier to the Food and Drug Administration (FDA) in the US. The FDA reviewer can ask questions at any time until the end of the review period, which may be at six or 10 months, during which time the applicant must be available to respond to any questions as quickly as possible. Because the timing of questions is not predictable, it can be more of a challenge to plan resources and puts pressure on the teams to determine their strategy for response in less time.

A number of techniques can help coordinate and manage the challenge of answering these questions (see Figure 1, page 80). The first is to get ready in advance. This consists of two steps: anticipating potential questions and then planning your response team.

It is helpful to start planning for potential questions while writing the dossier. There are usually a handful of obvious questions the authorities will want to explore in detail for every development programme: those gaps in the data, problems that arose while running the studies, differences of opinion about analysis methods or clinical practice, and so on, that become obvious while the drafts of the summaries are being written and reviewed internally. Making a list of all these issues is useful because it is likely that at least half of these appear as questions from the regulatory reviewers. Armed with this list, after the dossier has been sent off, the response team can focus on coming up with creative ways to explain each of these issues in more detail than they may have done in the dossier itself.

### Case Study

In practical terms, the following scenario is an example of how the techniques described in this article have been applied successfully. In this case, work began upon receipt of the day 80 set of initial questions from the rapporteur and co-rapporteur. The team assessed the questions, and first determined which seemed the most likely to be part of the final set of consolidated questions and would need considerable efforts to prepare the response for (due to the need for re-analyses, for example). These questions were assigned highest priority and the team began to gather the information needed for their responses.

When day 120 arrived, there were 84 clinical questions, including five sub-questions. Although some of the questions from the preliminary set had been removed, some new ones had been added. At this point, the lead medical writer created a tracking sheet for all 84 questions, including lines for each subquestion within a question. These questions were divided up and assigned to a team of seven medical writers. The clinical response team met and established their strategy for the messages and data needed to make effective arguments for each response, which was captured by the lead medical writer in the tracking sheet and communicated to the other assigned writers. The team of writers then began developing first drafts of the responses, interacting directly with the responsible authors from the clinical team to get information as needed, ask questions and develop ideas. The lead and/or responsible writer for a given response had meetings with the clinical team to discuss each draft and then implemented the feedback and any new data provided. Draft responses were sent to the team in bundles of five to 10 files to spread out the review workload and facilitate consolidation of feedback. Each morning the team of writers met to monitor progress and the lead writer updated the tracking sheet.

As needed, responses were reassigned with the team of writers on an ongoing basis to those who had capacity. In this way, there were no gaps in the writing activities. In the end, a compiled response document was produced that was 292 pages long and which had 17 appendices. All responses were final within 55 days after receipt of the day 120 consolidated list of questions (see Figure 3, page 88).

Thus, by applying the appropriate techniques, a mammoth task that could have been difficult to manage turned into a streamlined activity that was completed in record time. The input of the clinical team was optimally coordinated and efficient management of the writing and review process minimised downtime from start to finish. The writing and coordinating of responses to authority questions is always a stressful activity due to the very short time available. However, these good medical writing practices have been field tested repeatedly over the last 10 years, and have proven their worth in helping teams get the work done as efficiently as possible.
The lead writer should also ensure the team discusses and agrees on the review process, including setting binding timelines for when drafts are due and when review feedback is to be provided.
Preparing responses to authority questions is often similar to running a relay race. Numerous responses are written in parallel, with several documents at different stages of completion, all being passed among team members to review in a very short time frame.

	

The practical logistics of working with individual files for each response means, however, that responses need to be organised in the context of the final consolidated file of responses. This means the writing team needs to agree at the start on factors such as how to implement cross-referencing between responses or consistent use of abbreviations. Defining these things in advance saves a lot of headaches when it comes to compiling the final responses into a unified document.

Regular meetings with the response team are important to make sure everyone knows what others are doing and in order to prioritise activities. Use the tracking sheet to drive these meetings, updating the status of each response, identifying critical path activities (such as new activities that arise including the need for new analyses) and defining who is responsible for them.

There is a lot of activity happening in a short time frame, with anywhere from 10 to 100 different response documents being developed and reviewed simultaneously, so the timelines for when drafts are due and when review feedback is to be provided. It should be clear exactly who needs to review the response to which questions, and it is a good idea to put this information in the tracking sheet, so that it doesn’t get forgotten or overlooked. Will each response be reviewed once or twice? At which stage should it go to broader team review? Who is going to consolidate the feedback from each round of review? All these questions should be clarified in advance to avoid misunderstandings and make sure everyone knows what they need to do and when.

Ideally, each response should initially be written as a separate Word file. Although the responses will ultimately be pulled together into a consolidated document at the end, until each response gets to a final draft stage, it is much more effective to handle them separately from each other. Keeping each response as a separate entity until the end enables each one to be written and reviewed in isolation, so that work can continue on all others in parallel.

Communication and Agreement

Figure 3: A case study – European response writing

- 7 writers (using a well-managed process)
- Worked on
- 84 questions (including five sub-questions)
- and produced
- 292 pages as a compiled response file plus 17 additional appendices
- in just
- 55 days

lead medical writer sits at the eye of the storm, and holds the team together in these periods. They pull together input from different functions, coordinate parallel review cycles and meetings to discuss the outcome of these, and maintain an overview of progress by constantly updating the tracking sheet (see Figure 2). By understanding the role they play and setting up the process to enable them to apply their tricks of the trade, the whole experience can be simplified and made much more efficient for all involved.
Conclusion

Preparing responses to authority questions is often similar to running a relay race. Numerous responses are written in parallel, with several documents at different stages of completion, all being passed among team members to review in a very short time frame. And it is important that none of the documents fall between the cracks and get left behind in the process. With the assistance of an experienced medical writer, the process of writing and coordinating responses to authority questions can be made as efficient as possible and, ultimately, reduce the stress often associated with this activity.

References

1. Article 6(3) of Regulation (EC) No. 726/2004 of the European parliament and of the council of 31 March 2004, Laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
2. European Medicines Agency, Time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure, Doc Ref EMEA/75401/2006, Rev 2

About the author

Julia Forjanic Klapproth is a Senior Partner and CEO of Trilogy Writing and Consulting, a specialised medical writing company, which she co-founded in 2002. Aside from management activities, Julia also contributes to client projects, writing clinical documents from study protocols to submission dossiers. After receiving her PhD in Developmental Neurobiology, Julia started her career as a medical writer at Hoechst Marion Roussel in 1997. Since then she has been President of the European Medical Writers Association (EMWA) twice (2001-2002, 2007-2009). She is also an Auxiliary Professor of Science Communication in the Biomedical Science Department of the University of Aveiro, Portugal, and is an experienced trainer of medical writers, regularly running workshops for EMWA and pharmaceutical companies around the world.

Email: julia@trilogywriting.com